This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Imaging			
Detecting response to breast cancer neoadjuvant therapy with diffuse optical spectroscopic imaging (DOSI)	<p>A method that uses near-infrared imaging, called DOSI, could provide early detection of response to neoadjuvant therapy in breast cancer patients. In 23 primary breast cancer patients receiving neoadjuvant chemotherapy, DOSI of the tumor and peritumoral region with near-infrared light after one day of chemotherapy detected increased levels of oxygenated hemoglobin in complete and partial responders and decreased levels of oxygenated hemoglobin in nonresponders compared with pretreatment baselines. Planned work includes a clinical trial to validate these early responses.</p> <p>SciBX 4(32); doi:10.1038/scibx.2011.921 Published online Aug. 18, 2011</p>	Patented by the University of California, Irvine; licensed to Spectros Inc.	<p>Roblyer, D. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Aug. 15, 2011; doi:10.1073/pnas.1013103108</p> <p>Contact: Bruce Tromberg, University of California, Irvine, Calif. e-mail: bjtrombe@uci.edu</p>